Cabaletta Bio, Inc. (CABA) Form 10-Q — May 14, 2026
Cabaletta Bio, Inc. reported a net loss of $43.5 million for the three months ended March 31, 2026, compared to a net loss of $35.9 million for the same period in 2025. The increase in net loss is primarily due to higher research and development expenses, which rose by $8.3 million to $37.4 million in 2026. This increase reflects expanded cell processing capabilities and increased patient enrollment in clinical trials.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Total Debt
- 44841
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 148146
- Cash Position
- 116635
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 111324796
- Net Proceeds May2026 Financing
- 141000
Price after filing
1 day: 0.0%7 days: +2.2%30 days: -16.6%
Close on the filing date to close N calendar days later (from $3.61). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.